Clinical Advances and New Insights in the Management of Pediatric Atopic Dermatitis
October 5, 2020
Clinical Advances and New Insights in the Management of Pediatric Atopic Dermatitis is a Satellite Symposium hosted by The Masters of Pediartric Dermatology. In this symposia, expert faculty will lead problem-based learning and inquiry-oriented activities designed to demonstrate practical strategies for the diagnosis and treatment of pediatric AD. Any cases or questions submitted prior to the program will also be shared and addressed.
This activity is designed for an audience of physicians, nurses, pharmacists and other healthcare professionals.
Upon completion of the educational activity, participants should be able to:
- Identify AD based on the evaluation of clinical characteristics specific to infants, children, and adolescents
- Examine the efficacy and safety of current non-pharmacological and pharmacological treatments for AD patients across the age spectrum
- Define the rationale and mechanism of action for the use of new and emerging agents, including crisaborole, dupilumab, and oral JAK inhibitors in the management of AD
- Develop individualized treatment plans for pediatric patients with AD based on the efficacy and safety of current and new agents, treatment recommendations, and patient and caregiver preferences
Criteria for Success
If you have questions about this activity, please contact AKH Inc. at firstname.lastname@example.org. There is no fee for this activity.
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDERM. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 1.5 Contact Hours.
Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDERM
AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge -based activity for 1.5 contact hour(s) 0.15 CEUs). UAN 0077-9999-20-020-L04-P. Release Date: October 5, 2020
This activity is supported by an educational grant from Pfizer Inc.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.